Cannabis-Based Products in a Neurological Setting: A Clinical and Pharmacokinetic Survey.
cannabidiol
cannabis oil
cannabis oromucosal spray
delta-9-tetrahydrocannabinol
medical cannabis
neurology
pharmacokinetics
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
09
2021
accepted:
27
01
2022
entrez:
14
4
2022
pubmed:
15
4
2022
medline:
15
4
2022
Statut:
epublish
Résumé
Limited data are available in clinical settings on the pharmacokinetics of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). We investigated the use of cannabis-based products in neurological practice, monitoring patients' steady-state cannabinoids (CBs) plasma concentrations matched with different preparations. This was a prospective, single-center, observational study. Patients underwent venous blood withdrawal before the CBs' morning dose and then 2.5 h post-dosing. Spasticity or pain were patient self-assessed by the Numeric Rating Scale (NRS) before the morning CB's administration and 2.5 h post-dosing. Thirty-three patients were enrolled. Main indications for CBs were spasticity and chronic pain. Sixteen patients were treated with oromucosal spray formulation Sativex® and 17 with oil-based solutions. Both CBs trough plasma concentrations were ≤ limit of detection (0.1 ng/ml) in 45% of patients. Intrasubject CB's plasma levels significantly increased over baseline values in patients treated with Bediol® oil ( This is the first study investigating CB's plasma concentrations of oral and oromucosal preparations in real-world neurological practice. Findings of similar bioavailability for both CBD and THC after galenic oil compared with oromucosal spray dosing may be clinically relevant and deserve additional research in larger cohorts.
Sections du résumé
Background and Aim
UNASSIGNED
Limited data are available in clinical settings on the pharmacokinetics of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). We investigated the use of cannabis-based products in neurological practice, monitoring patients' steady-state cannabinoids (CBs) plasma concentrations matched with different preparations.
Methods
UNASSIGNED
This was a prospective, single-center, observational study. Patients underwent venous blood withdrawal before the CBs' morning dose and then 2.5 h post-dosing. Spasticity or pain were patient self-assessed by the Numeric Rating Scale (NRS) before the morning CB's administration and 2.5 h post-dosing.
Results
UNASSIGNED
Thirty-three patients were enrolled. Main indications for CBs were spasticity and chronic pain. Sixteen patients were treated with oromucosal spray formulation Sativex® and 17 with oil-based solutions. Both CBs trough plasma concentrations were ≤ limit of detection (0.1 ng/ml) in 45% of patients. Intrasubject CB's plasma levels significantly increased over baseline values in patients treated with Bediol® oil (
Conclusion
UNASSIGNED
This is the first study investigating CB's plasma concentrations of oral and oromucosal preparations in real-world neurological practice. Findings of similar bioavailability for both CBD and THC after galenic oil compared with oromucosal spray dosing may be clinically relevant and deserve additional research in larger cohorts.
Identifiants
pubmed: 35418935
doi: 10.3389/fneur.2022.784748
pmc: PMC8997238
doi:
Types de publication
Journal Article
Langues
eng
Pagination
784748Informations de copyright
Copyright © 2022 Mohamed, Lopane, Sabattini, Scandellari, Zardi, Donadio, Rizzo, Perrone, Lugaresi and Contin.
Déclaration de conflit d'intérêts
AL has served as a Biogen, Merck Serono, Novartis, Roche, Sanofi/Genzyme Bristol-Myers- Squibb Celgene, and Teva Advisory Board Member. She received congress, and travel/accommodation expense compensations or speaker honoraria from Biogen, Merck, Mylan, Novartis, Sanofi/Genzyme, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Her institutions received research grants from Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Neuropharmacol. 2018 Sep/Oct;41(5):171-176
pubmed: 30024443
Eur J Intern Med. 2018 Mar;49:12-19
pubmed: 29307505
Int J Gen Med. 2020 Dec 01;13:1317-1333
pubmed: 33299341
Adv Exp Med Biol. 2019;1162:151-165
pubmed: 31332738
Br J Pharmacol. 2015 Oct;172(20):4790-805
pubmed: 26218440
Handb Exp Pharmacol. 2011;(202):425-51
pubmed: 21290238
Br J Clin Pharmacol. 2018 Nov;84(11):2477-2482
pubmed: 30001569
Eur Rev Med Pharmacol Sci. 2018 Feb;22(4):1161-1167
pubmed: 29509270
Neurol Sci. 2018 Jan;39(1):97-102
pubmed: 29052091
Front Integr Neurosci. 2018 Oct 18;12:51
pubmed: 30405366
Medicina (Kaunas). 2020 May 15;56(5):
pubmed: 32429074
Aust J Gen Pract. 2021 Jun;50(6):345-350
pubmed: 34059837
Pharmaceuticals (Basel). 2021 Jan 06;14(1):
pubmed: 33418866
J Anal Toxicol. 2017 May 1;41(4):277-288
pubmed: 28069869
Medicina (Kaunas). 2020 Jun 23;56(6):
pubmed: 32585912
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52
pubmed: 22588748
Neurology. 2014 Apr 29;82(17):1556-63
pubmed: 24778283
Eur J Clin Pharmacol. 2018 Nov;74(11):1427-1436
pubmed: 29980818
Drugs. 2019 Sep;79(13):1435-1454
pubmed: 31372958
Front Pharmacol. 2018 Nov 26;9:1365
pubmed: 30534073
Eur J Clin Pharmacol. 2013 May;69(5):1135-47
pubmed: 23179176
Pain Ther. 2019 Jun;8(1):41-51
pubmed: 30721403
Drugs. 2018 Nov;78(16):1665-1703
pubmed: 30374797
Clin Ther. 2008 May;30(5):974-85
pubmed: 18555944
J Vet Pharmacol Ther. 2004 Dec;27(6):427-39
pubmed: 15601438
Clin Chem Lab Med. 2018 Mar 28;56(4):94-96
pubmed: 29176009
Talanta. 2021 Feb 1;223(Pt 2):121772
pubmed: 33298281
Ann Intern Med. 2017 Sep 05;167(5):319-331
pubmed: 28806817
Phytother Res. 2021 Mar;35(3):1646-1657
pubmed: 33155722
Front Pharmacol. 2021 Mar 03;12:637801
pubmed: 33746760
J Pharm Pharmacol. 2018 Jan;70(1):143-149
pubmed: 29057480